Polypoidal choroidal vasculopathy (PCV) is a multiple choroid vascular diseases in colored people and so on Asian, higher incidence in our country. Indocyanine green angiography showed a polypoid expansion of choroid blood vessels is recognized a gold standard for diagnosis of PCV．Always, PCV was seen as a subtype of wet age-related macular degeneration.But with the development of medicine, the pathogenesis of PCV arises controversy. PCV is an independent disease or subtypes of age-related macular degeneration is still no unified standard, PCV clinical diagnosis, optimal treatment options and prognosis is different from wet age-related macular degeneration. In this paper, the PCV clinical characteristics, imaging examination and clinical aspects is included. Although PCV pathogenesis is unclear, we believe that through our unremitting efforts,the diagnosis and understanding of PCV pathogenesis will improve．
[1]Wong LM, Lai YY.Polypoidal choroidal vasculopathy: an update on therapeutic approaches[J].J Ophthalmic Vis Res, 2013, 8(4):359-371
[2]Stern RM, Zakov ZN, Zegarra H, et al.Multiple recurrent serosanguineous retinal pigment epithelial detachments in black women[J].Am J Ophthalmol, 1985, 100(4):560-569
[3]Yannuzzi LA, Sorenson J, Spaide RF, et al.Idiopathic polypoidal choroidal vasculopathy (IPCV)[J].Retina, 1990, 10(1):1-8
[4]Gotoh N, Yamada R, Nakanishi H, et al.Correlation between CFH Y402H and HTRA1 rs11200638 genotype to typical exudative age-related macular degeneration and polypoidal choroidal vasculopathy phenotype in the Japanese population[J].Clin Experiment Ophthalmol, 2008, 36(5):437-442
[5]Cheng HC, Liu JH, Lee SM, et al.Hyperhomocysteinemia in Patients with Polypoidal Choroidal Vasculopathy: A Case Control Study[J].PLoS One, 2014, 9(10):e110818-e110818
[6]Wen F, Chen CZ, Wu DZ, et al.Polypoidal choroidal vasculopathy in elderly Chinese patients[J].Graefes Arch Clin Exp Ophthalmol, 2004, 242(8):625-629
[7]王小琴, 生侠, 谢青.息肉状脉络膜血管病变的研究进展[J].国际眼科纵览, 2013, 37(3):172-176
[8]Imamura Y, Engelbert M, Iida T, et al.Polypoidal choroidal vasculopathy: a review[J].Surv Ophthalmol, 2010, 55(6):501-515
[9]Rishi P, Rishi E, Mathur G, et al.Ocular perfusion pressure and choroidal thickness in eyes with polypoidal choroidal vasculopathy,wet- age- related macular degeneration and normals[J].Eye(Lond), 2013, 27(9):1038-1043
[10]刘雪霞.息肉样脉络膜血管病变的诊断与治疗进展[J].中华医学眼科杂志：电子版, 2013, 3(3):173-176
[11]Zuo CG, Wen F, Huang SZ, et a.Angiographic leakage of polypoidal choroidal vasculopathy on indocyanine angiography[J].Chin Med J(Engl), 2010, 123(12):1548-1552
[12]Coppens G, Spielberg L, Leys A.Polypoidal choroidal vasculopathy, diagnosis and management[J].[J].Bull Soc Belge Ophtalmol, 2011, 317:39-44
[13]文峰，吴德正，陈艳丽．. 渗出型老年性黄斑变性与息肉样脉络膜血管病变眼底形态学的对比分析[J].中华眼底病杂志, 2004, 20(5):307-309
[14]Sato T, Kishi S, Watanabe G, et al.Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy[J].Retina, 2007, 27(5):589-594
[15]Hou J, Tao Y, Li XX, et al.Clinical characteristics of polypoidal choroidal vasculopathy in Chinese patients[J].Graefes Arch Clin Exp Ophthalmol, 2011, 249(7):975-979
[16]刘冉，李加青，丁小燕，等.息肉样脉络膜血管病变得频域光相干断层扫描图像特征分析[J].中山大学学报：医学科学版, 2012, 33(6):841-847
[17]Japanese Study Group of Polypoidal Choroidal Vasculopathy.Criteria for diagnosis of polypoidal choroidal vasculopathy[J].Nihon Ganka Gakkai Zasshi, 2005, 109(7):417-427
[18]Otani A, Sasahara M, Yodoi Y, et al.Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy[J].Am J Ophthalmol, 2007, 144(1):7-14
[19]Japanese Study Group of Polypoidal Choroidal Vasculopathy.Criteria for diagnosis of polypoidal choroidal vasculopathy[J].Nihon Ganka Gakkai Zasshi, 2005, 109(7):417-427
[20]齐慧君, 黎晓新.治疗息肉状脉络膜血管病变的疗效观察[J].中国实用眼科杂志, 2006, 24(10):1021-1024
[21]Sugano Y, Iida T, Maruko I, et a.Choroidal thickness outside the laser irradiation area after photodynamie therapy in polypoidal ehoroidal vasculopathy[J].Jpn J Ophthalmol, 2013, 57(3):294-300
[22] Kang HM, Kim YM, Koh n J.Five-year follow-up results of photodynamie therapy for polypoidal choroidal vasculopathy[J].Am J
[23]Ophthalmol, 2013, 155(3):438-447.
[24]Silva RM, Figueira J, Cachulo ML, et al.Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin[J].Graefes Arch Clin Exp Ophthalmol, 2005, 243(10):973-
[25]Hirami Y, Tsujikawa A, Otani A, et a.Hemorrhagic complications after photodynamic therapy for polypoidal ehoroidal vaseulopathy[J].Retina, 2007, 27(3):335-341
[26]Hikichi T, Higuchi M, Matsushita T, et al.One-Year Results of Three Monthly Ranibizumab Injections and As-Needed Reinjections for Polypoidal Choroidal Vasculopathy in Japanese Patients[J].Am J Ophthalmol, 2012, 154(1):117-124
[27]Kang H, Koh H.Two-year outcome after combination therapy for polypoidal choroidal vasculopathy: comparison with photodynamic monotherapy and anti-vascular endothelial growth factor monotherapy[J].Ophthalmologica, 2013, 231(2):86-93
[28]Gomi F, Sawa M, Wakabayashi T, et al.Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy[J].Am J Ophthalmol, 2010, 150(1):48-54
[29]Maruko I, Iida T, Sugano Y, et al.Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy[J].Am J Ophthalmol 2011, 151(4):594-603.
[30] Tomita K, Tsujikawa A, Yamashiro K, et al.Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab[J].Am J Ophthalmol 2012, 153(1):68-80.
